Immune checkpoints in osteosarcoma: Recent advances and therapeutic potential

Area of Science:

• Oncology
• Immunotherapy
• Bone Cancer Research

Background:

• Osteosarcoma is the most frequent primary malignant bone tumor, characterized by high recurrence and metastasis rates.
• Current treatments for advanced osteosarcoma have seen limited progress over the last 40 years.
• Immune checkpoint inhibitors (ICIs) have revolutionized cancer treatment, presenting a potential new strategy for osteosarcoma.

Purpose of the Study:

• To review recent advancements in immune checkpoints, including PD-1, PD-L1, and CTLA-4, and their application in osteosarcoma.
• To elucidate the primary mechanisms of resistance to ICI therapy in osteosarcoma.
• To summarize current strategies aimed at enhancing ICI efficacy and identify potential predictive biomarkers for osteosarcoma treatment.

Main Methods:

• Literature review of immune checkpoints and their role in osteosarcoma.
• Analysis of existing research on ICI resistance mechanisms.
• Synthesis of data on strategies to improve ICI efficacy and predictive biomarkers.

Main Results:

• Discussion of programmed cell death protein-1 (PD-1), programmed cell death protein ligand-1 (PD-L1), and cytotoxic T lymphocyte-associated antigen-4 (CTLA-4) in osteosarcoma.
• Identification of key resistance mechanisms limiting ICI effectiveness.
• Overview of therapeutic strategies and biomarkers for optimizing osteosarcoma immunotherapy.

Conclusions:

• ICIs represent a promising therapeutic avenue for osteosarcoma, despite existing challenges.
• Understanding resistance mechanisms and identifying predictive biomarkers are crucial for successful ICI implementation.
• Further research into combination therapies and biomarker development is warranted to improve osteosarcoma patient outcomes.